Cargando…
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
IMPORTANCE: To our knowledge, this multicenter analysis is the first to test and validate (1) the prognostic impact of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2) a novel, risk-stratifying composite model incorporating comorbidities, age, and cytog...
Autores principales: | Sorror, Mohamed L., Storer, Barry E., Fathi, Amir T., Gerds, Aaron T., Medeiros, Bruno C., Shami, Paul, Brunner, Andrew M., Sekeres, Mikkael A., Mukherjee, Sudipto, Peña, Esteban, Elsawy, Mahmoud, Wardyn, Shylo, Whitten, Jennifer, Moore, Rachelle, Becker, Pamela S., McCune, Jeannine S., Appelbaum, Frederick R., Estey, Elihu H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824273/ https://www.ncbi.nlm.nih.gov/pubmed/28880971 http://dx.doi.org/10.1001/jamaoncol.2017.2714 |
Ejemplares similares
-
Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018) -
Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020) -
Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022) -
Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016) -
Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)